The effect of pre-stenting on bleeding-related complications following ureteroscopy in patients on anticoagulation or antiplatelet therapy.

The American Urological Association guidelines state that continuing anticoagulation (AC) and antiplatelet (AP) agents during ureteroscopy (URS) is safe. Through a multi-institutional retrospective study, we sought to determine whether pre-stenting in patients on AP or AC was associated with fewer URS bleeding-related complications.

A series of 8,614 URS procedures performed across three institutions (April 2010 - September 2017) was electronically reviewed for AC/AP use at time of URS. Records indicating AC or AP use at time of URS were then manually reviewed to characterize intraoperative and 30-day postoperative (intraoperative bleeding, postoperative hematuria, emergency department visits, hospital readmission, unplanned reoperation, phone calls, and other minor 30-day complications).

A total of 293 identified URS procedures were completed on patients on AC/AP therapy-112 cases were on AC only (38 were pre-stented), 158 on AP only (51 pre-stented), and 23 on both AP and AC (8 pre-stented). Patient characteristics and comorbidities were similar between the pre-stented and non-pre-stented groups. For AC and AP subjects, pre-stenting did not decrease the composite risk of bleeding complications (10.3% pre-stent vs 12.2% non-pre-stent, p=0.6). Pre-stented patients did have a significantly lower likelihood of requiring an unplanned reoperation (1.0% vs 5.6%, p=0.04). In the subgroup of patients on AP alone, pre-stented patients had significantly fewer episodes of intraoperative bleeding (0% vs 9%, p=0.04), unplanned reoperations (0% vs 6.5%, p=0.02), and 30-day complications (14% vs 27%, p=0.05). In the subgroup of patients on AC alone, there were no significant differences in outcomes based on stent status.

In this multi-institutional study, we found that pre-stenting before URS was not associated with fewer bleeding complications. However, pre-stenting appeared to be associated with improved outcomes for those patients on AP therapy. These results suggest a need for prospective studies to clarify the role of pre-stenting for URS.

Journal of endourology. 2023 Sep 07 [Epub ahead of print]

Jonathan Henry Berger, Thomas DiPina, Luay Alshara, Carlos Alfredo Batagello, Joshua Heiman, Tim Large, Sri Sivalingam, Roger L Sur, Amy Krambeck, Seth K Bechis

University of California San Diego, 8784, Urology, UC San Diego Health, 200 West Arbor Drive #8897, San Diego, CA 92103-7897, La Jolla, California, United States, 92093-0021; ., University of California San Diego Health System, 21814, Urology, San Diego, California, United States; ., Albany Medical Center, 138207, Glickman Urology and Kidney Institute, Cleveland, Ohio, United States; ., Universidade de Sao Paulo Hospital das Clinicas, 117265, Section of Endourology, Division of Urology, Sao Paulo, São Paulo, Brazil; ., Indiana University School of Medicine, 12250, Urology, Indianapolis, Indiana, United States; ., Indiana University School of Medicine, 12250, Urology, 1801 N Senate Blvd, Suite 220, Indianapolis, Indiana, United States, 46202; ., University of Wisconsin-Madison, 5228, Urology, Madison, Wisconsin, United States; ., UC San Diego, 8784, Urology, San Diego, California, United States; ., Northwestern University Feinberg School of Medicine, 12244, Urology, Chicago, Illinois, United States; ., University of California San Diego Health System, 21814, Urology, San Diego, California, United States; .